Skip to main
MET

MetLife (MET) Stock Forecast & Price Target

MetLife (MET) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

MetLife is attractive because its valuation remains below higher-rated life insurers even after a ~23% YTD rally, suggesting the market may still underappreciate its strategic execution and improving business mix. Its capital-light franchises—Group Benefits, Latin America, EMEA, and MetLife Investment Management—support high free cash flow and a 17% ROE in 2Q’26, with Group Benefits’ broad product suite and high-90% persistency reinforcing durable earnings. Further upside comes from leadership in Latin America and steadier variable investment income around $1.6 billion, while the U.S. businesses and rising rates should help sustain earnings and support a re-rating.

Bears say

MetLife is viewed negatively because its earnings are exposed to several volatile drivers, including interest rates, credit spreads, market-sensitive alternative investments, and pension risk transfer activity, which can create cash flow and liability instability. Although the stock appears inexpensive at about 9.6x 2026E P/E and 8.8x 2027E P/E versus peers at 10.3x and 9.3x, that valuation is tempered by the risk that favorable mortality and recent investment tailwinds may normalize or reverse. Competition across group benefits, RIS, Asia, Latin America, EMEA, and investment management, plus geopolitical exposure in international regions, could compress fees and margins and weigh on 2025 and 2024 earnings contributions.

MetLife (MET) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MetLife and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MetLife (MET) Forecast

Analysts have given MetLife (MET) a Buy based on their latest research and market trends.

According to 12 analysts, MetLife (MET) has a Buy consensus rating as of Oct 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MetLife (MET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.